Phio Pharmaceuticals (PHIO) Research & Development (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Research & Development came in at $2.8 million in Q1 2026, up 215.24% YoY from $886000.0 in Q1 2025, and up 136.49% on a QoQ basis from $1.2 million in Q3 2025.
Phio Pharmaceuticals (PHIO) Research & Development (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Research & Development data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Research & Development rose 215.24% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 75.51% YoY) and the FY2024 annual result came in at $3.6 million, down 42.47% from the prior year.
- Research & Development grew to $2.8 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.8 million in Q1 2026 to a low of $644000.0 in Q3 2024.
- A 5-year average of $1.4 million and a median of $1.2 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development plunged 81.84% — and 2026, when it jumped 215.24%.
- Tracing PHIO's Research & Development over 5 years: stood at $1.6 million in 2022, then tumbled by 37.61% to $1.0 million in 2023, then retreated by 2.18% to $985000.0 in 2024, then rose by 19.9% to $1.2 million in 2025, then soared by 136.49% to $2.8 million in 2026.
- The last three Research & Development figures came in at $2.8 million (Q1 2026), $1.2 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 3.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.08 Mn |
| Mar 31, 2026 | 2.79 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 886,000.00 |
| Dec 31, 2024 | 985,000.00 |
| Sep 30, 2024 | 644,000.00 |
| Jun 30, 2024 | 866,000.00 |
| Mar 31, 2024 | 1.15 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 2.13 Mn |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 2.51 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.59 Mn |
| Dec 31, 2021 | 8.89 Mn |
| Sep 30, 2021 | 2.67 Mn |
| Jun 30, 2021 | 1.56 Mn |